CBL is an inclusion criterion in 4 clinical trials for acute myeloid leukemia, of which 3 are open and 1 is closed. Of the trials that contain CBL status and acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (0 open), and 2 are phase 2 (2 open) [4].

CBL is an inclusion criterion in 3 clinical trials for chronic myelomonocytic leukemia, of which 3 are open and 0 are closed. Of the trials that contain CBL status and chronic myelomonocytic leukemia as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [4].

CBL is an inclusion criterion in 3 clinical trials for myelodysplastic syndromes, of which 3 are open and 0 are closed. Of the trials that contain CBL status and myelodysplastic syndromes as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [4].

CBL is an inclusion criterion in 1 clinical trial for acute myeloid leukemia arising from previous myelodysplastic syndrome, of which 1 is open and 0 are closed. Of the trial that contains CBL status and acute myeloid leukemia arising from previous myelodysplastic syndrome as inclusion criteria, 1 is phase 1 (1 open) [4].

CBL is an inclusion criterion in 1 clinical trial for B-cell acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains CBL status and B-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

CBL is an inclusion criterion in 1 clinical trial for hepatocellular carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CBL status and hepatocellular carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CBL is an inclusion criterion in 1 clinical trial for juvenile myelomonocytic leukemia, of which 1 is open and 0 are closed. Of the trial that contains CBL status and juvenile myelomonocytic leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

CBL is an inclusion criterion in 1 clinical trial for myelodysplastic syndrome with excess blasts-2, of which 1 is open and 0 are closed. Of the trial that contains CBL status and myelodysplastic syndrome with excess blasts-2 as inclusion criteria, 1 is phase 2 (1 open) [4].

CBL is an inclusion criterion in 1 clinical trial for myelodysplastic/myeloproliferative neoplasm, of which 1 is open and 0 are closed. Of the trial that contains CBL status and myelodysplastic/myeloproliferative neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

CBL is an inclusion criterion in 1 clinical trial for myelodysplastic/myeloproliferative neoplasm, unclassifiable, of which 1 is open and 0 are closed. Of the trial that contains CBL status and myelodysplastic/myeloproliferative neoplasm, unclassifiable as inclusion criteria, 1 is phase 1 (1 open) [4].

CBL is an inclusion criterion in 1 clinical trial for myeloid neoplasm, of which 1 is open and 0 are closed. Of the trial that contains CBL status and myeloid neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

CBL is an inclusion criterion in 1 clinical trial for neurofibromatosis type 1, of which 1 is open and 0 are closed. Of the trial that contains CBL status and neurofibromatosis type 1 as inclusion criteria, 1 is phase 2 (1 open) [4].

CBL is an inclusion criterion in 1 clinical trial for non-small cell lung carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CBL status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 2 (0 open) [4].

CBL is an inclusion criterion in 1 clinical trial for secondary acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains CBL status and secondary acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) [4].

CBL is an inclusion criterion in 1 clinical trial for T-cell acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains CBL status and T-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

CBL is an inclusion criterion in 1 clinical trial for therapy-related acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains CBL status and therapy-related acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) [4].

CBL is an inclusion criterion in 1 clinical trial for therapy-related myelodysplastic syndrome, of which 1 is open and 0 are closed. Of the trial that contains CBL status and therapy-related myelodysplastic syndrome as inclusion criteria, 1 is phase 1 (1 open) [4].